Cargando…

ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario

BACKGROUND: Anaplastic lymphoma kinase (ALK) inhibitors have shown significant efficacy in ALK -rearranged non-small cell lung cancer (NSCLC) patients with good performance status (PS) in multiple randomised studies. However, there is limited data on patients with poor performance status. PATIENTS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Ajaykumar, Kapoor, Akhil, Noronha, Vanita, Patil, Vijay, Menon, Nandini, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendru, Kaushal, Rajiv, Prabhash, Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377804/ https://www.ncbi.nlm.nih.gov/pubmed/36072236 http://dx.doi.org/10.3332/ecancer.2022.1407

Ejemplares similares

Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review
por: Khaddar, Satvik, et al.
Publicado: (2022)

Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
por: Kapoor, Akhil, et al.
Publicado: (2022)

Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2020)

Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings
por: Kapoor, Akhil, et al.
Publicado: (2022)

Association of Immune-Related Adverse Effects and Survival in Solid Tumor Patients Treated with PD1 Inhibitors
por: Kapoor, Akhil, et al.
Publicado: (2022)

Leptomeningeal metastasis from non-small cell lung cancer— a post-hoc analysis from four randomised clinical trials
por: Patil, Vijay, et al.
Publicado: (2022)

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience
por: Noronha, Vanita, et al.
Publicado: (2020)

Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?
por: Joshi, Amit, et al.
Publicado: (2017)

Small cell carcinoma of the oesophagus: experience of an Indian Tertiary Cancer Centre
por: Panda, Goutam Santosh, et al.
Publicado: (2022)

ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country
por: Noronha, Vanita, et al.
Publicado: (2016)

Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
por: Tibdewal, Anil, et al.
Publicado: (2021)

Systemic therapy for limited stage small cell lung carcinoma
por: Noronha, Vanita, et al.
Publicado: (2020)

A real‐world data of Immune checkpoint inhibitors in solid tumors from India
por: Noronha, Vanita, et al.
Publicado: (2021)

An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

ROS1 mutation non-small cell lung cancer—access to optimal treatment and outcomes
por: Joshi, Amit, et al.
Publicado: (2019)

Characteristics and clinical outcomes of pulmonary sarcomatoid carcinoma: experience from Tata Memorial Centre
por: Bondili, Suresh Kumar, et al.
Publicado: (2022)

Exploring the implications of modified advanced lung cancer inflammation index on outcomes in patients with advanced non-small cell lung cancer
por: Mahajan, Abhishek, et al.
Publicado: (2023)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients
por: Noronha, Vanita, et al.
Publicado: (2014)

Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer
por: Mahajan, Abhishek, et al.
Publicado: (2023)

Real-world analysis of the use of lenvatinib in differentiated thyroid cancers
por: Peelay, Zoya, et al.
Publicado: (2023)

Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center
por: Pandey, Avinash Vijaykumar, et al.
Publicado: (2015)

Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer
por: Patil, Vijay, et al.
Publicado: (2019)

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
por: Talreja, Vikas T., et al.
Publicado: (2019)

Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2019)

Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1–5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial
por: Tibdewal, Anil, et al.
Publicado: (2021)

Study of Treatment Outcome in Adults with TFE-Related RCC
por: Singh, Ajaykumar Chandrabhan, et al.
Publicado: (2021)

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy
por: Noronha, Vanita, et al.
Publicado: (2017)

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
por: Joshi, Amit, et al.
Publicado: (2018)

ALK1 Gene Rearranged Pulmonary Sarcomatoid Carcinoma Masquerading as Tuberculosis in a Young Male
por: Sahay, Ayushi, et al.
Publicado: (2021)

Multidisciplinary brain metastasis clinic: is it effective and worthwhile?
por: Rajpurohit, Annu, et al.
Publicado: (2020)

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
por: Joshi, Amit, et al.
Publicado: (2017)

Treatment pattern and outcomes in de novo T790M-mutated non-small cell lung cancer
por: Panda, Goutam Santosh, et al.
Publicado: (2022)

Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report
por: Abhishek, Mahajan, et al.
Publicado: (2022)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study
por: Patil, Vijay, et al.
Publicado: (2021)

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
por: Majumdar, Swaratika, et al.
Publicado: (2018)

Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer
por: Behel, Vichitra, et al.
Publicado: (2022)

Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?
por: Patil, Vijay M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0jna07qj2cmle9ts7e0ev15ibm